Lixte Biotechnology Holdings LIXT 深 滬
已收盤 09-05 16:00:00 美东时间
4.57
+0.100
+2.24%
華盛通- 最 高4.80
- 今 開4.53
- 成交量 9.44万股
- 最 低 4.3977
- 昨 收 4.47
- 總市值 2084.56万
- 52周最高 5.14
- 市盈率 靜 --
- 換手率 2.07%
- 52周最低 0.64
- 委 比 84.80%
- 總股本 456.14万
- 歷史最高 71.90
- 量 比 0.81
- 振 幅 9.00%
- 歷史最低 0.64
- 每 手 1
- 風險率 0.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lixte Biotechnology appoints new CFO and board members
Lixte Biotechnology (NASDAQ:LIXT) appointed Peter Stazzone as chief financial officer. Lourdes Felix and Guy Primus joined LIXTE’s board of directors. Former CFO Robert Weingarten and board members Ba...
09-03 20:18
LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
LIXTE Biotechnology Holdings announced the addition of Peter Stazzone as Chief Financial Officer and Lourdes Felix and Guy Primus to its Board of Directors, succeeding Bas van der Baan and René Bernards. The company has relocated its headquarters to Boca Raton, Florida, aiming to enhance operational efficiency and reduce costs. Stazzone brings over 20 years of financial management experience, while Felix and Primus add expertise in corporate fina...
09-03 12:00
24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
LIXTE Biotechnology Holdings, Inc. is advancing its lead compound, LB-100, in clinical trials targeting MSS colorectal cancer, ovarian clear-cell carcinoma, and soft-tissue sarcoma. LB-100 aims to enhance chemotherapy and immunotherapy effectiveness. Trials in MSS colorectal cancer, ovarian clear-cell carcinoma, and soft-tissue sarcoma are ongoing, with interim data expected soon. The company focuses on high-need cancer indications via combinatio...
08-25 12:05
24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
LIXTE Biotechnology’s lead compound LB-100, a first-in-class PP2A inhibitor, is highlighted in a Nature Reviews Cancer editorial for its innovative approach to cancer therapy. Unlike traditional methods, LB-100 hyperactivates oncogenic pathways, pushing cancer cells into a stress-induced collapse, and has shown promise in preclinical and clinical studies, including tumor regression in colorectal and pancreatic models. The compound’s mechanism, wh...
08-19 15:18
LIXTE Biotechnology Holdings Provides Corporate Update
LIXTE Biotechnology Holdings, Inc. has completed two financings, raising $6.5 million, and regained compliance for continued listing on Nasdaq. The company appointed Geordan Pursglove as Chairman and CEO, and Bas van der Baan as President and Chief Scientific Officer. Two new board members, Jason Sawyer and Michael Holloway, MD, were added. LIXTE’s compound LB-100 received validation through a study published in *Nature*, showing improved surviva...
08-18 12:00
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
LIXTE Biotechnology Holdings announced advancements in its lead compound LB-100, a first-in-class PP2A inhibitor targeting ovarian clear cell carcinoma, advanced soft tissue sarcoma, and MSS metastatic colon cancer. Upcoming 2025 catalysts include interim efficacy data for OCCC (Q4), PFS/ORR updates for STS (Q3), and biomarker data for MSS colon cancer (Q4). LB-100's potential to enhance DNA damage response and overcome treatment resistance posit...
08-14 12:05
每日数字货币动态汇总（2025-08-14）
1. 特朗普家族支持的矿企ABTC加速增持比特币，目前储备量达2130枚BTC 特朗普家族支持的美国比特币公司（ABTC）近期加速了比特币的收购，于7月1日至...
08-14 09:04
24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy
LIXTE Biotechnology Holdings announced a new treasury policy allowing up to 25% of its corporate reserves to be allocated to cryptocurrencies, including Bitcoin, to diversify its assets and enhance shareholder value while hedging against inflation and fiat currency depreciation.
08-13 12:49
LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency
LIXTE Biotechnology Holdings, Inc. has approved a strategic plan to allocate up to 25% of its corporate treasury to cryptocurrencies, including Bitcoin, to hedge existing assets and generate returns. Transactions will be based on market conditions and regulatory compliance, with assets held by a regulated custodian. The move reflects the company's long-term vision for growth and enhancing shareholder value.
08-13 11:30
Lixte Biotech Hldgs Q2 EPS $(0.29) Up From $(0.45) YoY
Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.29) per share. This is a 35.56 percent increase over losses of $(0.45) per share from the same period last year.
08-07 21:03
